35 related articles for article (PubMed ID: 38116741)
1. Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
Huang H; Liu Z; Ma Y; Shao Y; Yang Z; Duan D; Zhao Y; Wen S; Tian J; Liu Y; Wang Z; Yue D; Wang Y
Prostate; 2024 Mar; 84(4):376-388. PubMed ID: 38116741
[TBL] [Abstract][Full Text] [Related]
2. Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram.
Cheng Y; Fan B; Fu Y; Yin H; Lu J; Li D; Li X; Qiu X; Guo H
BMC Urol; 2024 Apr; 24(1):76. PubMed ID: 38566091
[TBL] [Abstract][Full Text] [Related]
3. Deep learning model for the detection of prostate cancer and classification of clinically significant disease using multiparametric MRI in comparison to PI-RADs score.
Yang C; Li B; Luan Y; Wang S; Bian Y; Zhang J; Wang Z; Liu B; Chen X; Hacker M; Li Z; Li X; Wang Z
Urol Oncol; 2024 May; 42(5):158.e17-158.e27. PubMed ID: 38388243
[TBL] [Abstract][Full Text] [Related]
4. Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.
Haj-Mirzaian A; Burk KS; Lacson R; Glazer DI; Saini S; Kibel AS; Khorasani R
JAMA Netw Open; 2024 Mar; 7(3):e244258. PubMed ID: 38551559
[TBL] [Abstract][Full Text] [Related]
5. Radiomics from multisite MRI and clinical data to predict clinically significant prostate cancer.
Krauss W; Frey J; Heydorn Lagerlöf J; Lidén M; Thunberg P
Acta Radiol; 2024 Mar; 65(3):307-317. PubMed ID: 38115809
[TBL] [Abstract][Full Text] [Related]
6. MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Huang C; Song G; Wang H; Ji G; Li J; Chen Y; Fan Y; Fang D; Xiong G; Xin Z; Zhou L
Biomed Res Int; 2018; 2018():6368309. PubMed ID: 30276213
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions.
Brancato V; Aiello M; Basso L; Monti S; Palumbo L; Di Costanzo G; Salvatore M; Ragozzino A; Cavaliere C
Sci Rep; 2021 Jan; 11(1):643. PubMed ID: 33436929
[TBL] [Abstract][Full Text] [Related]
8. Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA.
Benidir T; Lone Z; Wood A; Abdallah N; Campbell R; Bajic P; Purysko A; Nguyen JK; Kaouk J; Haber GP; Eltemamy M; Stein R; Haywood S; Klein EA; Almassi N; Campbell SC; Abouassaly R; Weight CJ
Urology; 2023 Jun; 176():115-120. PubMed ID: 36965817
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Radiological Factors for Predicting Clinically Significant Prostate Cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions.
Zhang Z; Hu C; Lin Y; Song O; Gong D; Zhang X; Wang N
Technol Cancer Res Treat; 2024; 23():15330338241246636. PubMed ID: 38629205
[TBL] [Abstract][Full Text] [Related]
10. Combination of prostate volume and apparent diffusion coefficient can stratify patients with a PI-RADS score of 3 to reduce unnecessary prostate biopsies.
Dong Q; Wang C; Shen D; Ma Y; Zhang B; Xu S; Tao T; Xiao J
Prostate; 2024 Jun; 84(8):780-787. PubMed ID: 38558415
[TBL] [Abstract][Full Text] [Related]
11. Prostate Health Index (PHI) as a triage tool for reducing unnecessary magnetic resonance imaging (MRI) in patients at risk of prostate cancer.
Agnello L; Vidali M; Salvaggio G; Agnello F; Lo Sasso B; Gambino CM; Ciaccio M
Clin Biochem; 2024 May; 127-128():110759. PubMed ID: 38583655
[TBL] [Abstract][Full Text] [Related]
12. Nomograms for predicting clinically significant prostate cancer in men with PI-RADS-3 biparametric magnetic resonance imaging.
Liang Z; Feng T; Zhou Y; Yang Y; Sun Y; Zhou Z; Yan W; Cao F
Am J Cancer Res; 2024; 14(1):73-85. PubMed ID: 38323293
[TBL] [Abstract][Full Text] [Related]
13. Different diagnostic strategies combining prostate health index and magnetic resonance imaging for predicting prostate cancer: A multicentre study.
Zhu M; Fu Q; Zang Y; Shao Z; Zhou Y; Jiang Z; Wang W; Shi B; Chen S; Zhu Y
Urol Oncol; 2024 May; 42(5):159.e17-159.e23. PubMed ID: 38480077
[TBL] [Abstract][Full Text] [Related]
14. Novel clinical risk calculator for improving cancer predictability of mpMRI fusion biopsy in prostates.
Bruccoliere A; Tran V; Helo N; Awal A; Stroever S; de Riese WTW
Int Urol Nephrol; 2024 Apr; ():. PubMed ID: 38578393
[TBL] [Abstract][Full Text] [Related]
15. Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies.
Osses DF; Arsov C; Schimmöller L; Schoots IG; van Leenders GJLH; Esposito I; Remmers S; Albers P; Roobol MJ
J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33321791
[TBL] [Abstract][Full Text] [Related]
16. A novel model incorporating quantitative contrast-enhanced ultrasound into PI-RADSv2-based nomogram detecting clinically significant prostate cancer.
Huang K; Luo L; Hong R; Zhao H; Li Y; Jiang Y; Feng Y; Fu Q; Zhou H; Li F
Sci Rep; 2024 May; 14(1):11083. PubMed ID: 38745087
[TBL] [Abstract][Full Text] [Related]
17. A novel nomogram to predict clinically significant prostate cancer in MR assisted lesion biopsies: Turkish uroocology association nomogram.
Şahin B; Çetin S; Sözen S; Aslan G; Çelik S; Türkeri L
Urol Oncol; 2024 May; ():. PubMed ID: 38782675
[TBL] [Abstract][Full Text] [Related]
18. Investigation of radiomics models for predicting biochemical recurrence of advanced prostate cancer on pretreatment MR ADC maps based on automatic image segmentation.
Wang H; Wang K; Ma S; Gao G; Wang X
J Appl Clin Med Phys; 2024 Apr; 25(4):e14244. PubMed ID: 38146796
[TBL] [Abstract][Full Text] [Related]
19. Should PI-RADS 3 be Subclassified According to ADC Values in the Transition Zone?
Teica RV; Ciofiac CM; Florescu LM; Gheonea IA
Curr Health Sci J; 2023; 49(4):564-570. PubMed ID: 38559832
[TBL] [Abstract][Full Text] [Related]
20. Radiomic nomogram based on bi-parametric magnetic resonance imaging to predict the International Society of Urological Pathology grading ≥ 3 prostate cancer: a multicenter study.
Zhang Y; Li Z; Gao C; Zhang L; Huang Y; Qu H; Shu C; Wei Y; Xu M; Cui F
Clin Radiol; 2024 Apr; ():. PubMed ID: 38763807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
